Oncotarget

Research Papers:

Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients

Yuhan Wang, Yingying Han, Qiang Weng and Zhengrong Yuan _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:65770-65781. https://doi.org/10.18632/oncotarget.11664

Metrics: PDF 453 views  |   HTML 785 views  |   ?  


Abstract

Yuhan Wang1, Yingying Han1, Qiang Weng1, Zhengrong Yuan1

1College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People’s Republic of China

Correspondence to:

Zhengrong Yuan, email: zryuan@bjfu.edu.cn

Keywords: XPG, rs2296147, cancer, clinical outcomes, meta-analysis

Received: May 24, 2016     Accepted: August 11, 2016     Published: August 29, 2016

ABSTRACT

The Xeroderma pigmentosum complementation group G (XPG) rs2296147T>C polymorphism is suspected to associate with the clinical outcomes of cancer patients. However, the results are inconsistent. This meta-analysis aimed to evaluate the reliable predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. A total of 11 eligible studies were enrolled in this meta-analysis. Our results indicated that the cancer patients with TT and CT genotypes were significantly associated with better respond rates when compared with the CC genotype (TT versus (vs.) CC: odds ratio (OR) = 2.05, 95% confidence intervals (CIs), 1.32-3.20, P = 0.002; TT+CT vs. CC: OR= 1.57, 95% CI, 1.14-2.17, P = 0.005). The TT genotype and/or T allele might be associated with higher survival time for cancer patients than the CC genotype and/or C allele. The cumulative meta-analyses showed an apparent beneficial objective response of TT genotype on cancer patients. In conclusion, this meta-analysis suggests that the XPG rs2296147T>C polymorphism is associated with the clinical outcomes of cancer patients. The XPG rs2296147T>C polymorphism might be a predictive factor of prognosis in cancers patients and contribute to individual treatment in the future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11664